A long-overlooked antibiotic is sparking new attention in the Lyme disease debate. Two recent studies report that this FDA-approved drug showed strong activity against Lyme bacteria in lab settings at far lower doses than standard treatments—while appearing to spare the gut microbiome. Early findings even suggest potential preventive uses. Now many are asking why this option hasn’t been explored more widely.
Old Antibiotic Shows Promise Against Lyme Disease at Ultra-Low Doses
